论文部分内容阅读
缺血性心肌病作为冠状动脉粥样硬化性心脏病终末期的一种类型,病死率高,预后差。目前临床多采用药物及血运重建治疗缺血性心肌病。与药物治疗相比,血运重建能有效改善心肌供血供氧,恢复心功能,提高患者生存率。现综合近年国内外运用血运重建治疗缺血性心肌病的研究,主要介绍:①经皮冠状动脉介入治疗,裸金属支架,药物涂层支架,生物可降解支架;②经皮冠状动脉介入治疗与冠状动脉搭桥临床作用比较;③治疗性血管再生等治疗方法对该病中远期预后的影响。随着科技的不断进步与医疗水平的不断提高,血运重建的临床效益亦将逐步提高。但无论使用哪一种血运重建方法,均必须与药物结合,控制好血压、血脂、血糖等危险因素,才能最大限度地改善患者的中远期预后。
Ischemic cardiomyopathy as a type of coronary atherosclerotic heart disease end stage, high mortality, poor prognosis. The current clinical use of drugs and revascularization in the treatment of ischemic cardiomyopathy. Compared with medical treatment, revascularization can effectively improve myocardial oxygen supply, restore cardiac function and improve patient survival. Now integrated in recent years, the use of revascularization at home and abroad for the treatment of ischemic cardiomyopathy research, mainly introduced: ① percutaneous coronary intervention, bare metal stent, drug-coated stent, biodegradable stent; ② percutaneous coronary intervention And coronary artery bypass graft compared with the clinical role; ③ therapeutic angiogenesis and other treatment of the disease in the long-term prognosis. With the continuous improvement of science and technology and continuous improvement of medical care, the clinical benefit of revascularization will also be gradually increased. However, no matter which method of revascularization is used, it must be combined with drugs to control the risk factors such as blood pressure, blood lipids, blood glucose and so on, in order to maximize the long-term prognosis of patients.